Cutaneous toxicities of new treatments for melanoma

• A. Boada ^[1] ; C. Carrera ^[2] ; S. Segura ^[3] ; H. Collgros ^[4] ; P. Pasquali ^[6] ; D. Bodet ^[5] ; S. Puig ^[2] ; J. Malvehy ^[2]
  1. [1] Hospital Universitari Germans Trias i Pujol

     Hospital Universitari Germans Trias i Pujol

     Barcelona, España

     
  2. [2] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
  3. [3] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  4. [4] Royal Prince Alfred Hospital

     Royal Prince Alfred Hospital

     Australia

     
  5. [5] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  6. [6] Pius Hospital Valls, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 11 (November 2018), 2018, págs. 1373-1384
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • New drugs against advanced melanoma have emerged during last decade. Target therapy and immunotherapy have changed the management of patients with metastatic disease. Along with its generalized use, drug toxicities have appeared and the skin is the target organ of a significant part of them. This revision summarizes the most common side effects and consensus management to improve the compliance of therapies and patients’ quality of life. Among the BRAF inhibitors, main cutaneous side effects are photosensitivity, plantar hyperkeratosis, and the appearance of verrucal keratosis or squamous cell carcinoma. Special attention must be paid to the development of new primary melanomas or changes on nevi during BRAF inhibitor therapy. The most common cutaneous side effects of immunotherapy are rash, pruritus, and vitiligo. It remains controversial the possible role of these toxicities as markers of response to therapy.